Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 2/20 | 0.57 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.57 |
| ▸ | ADAM17 | P78536 | 13/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | MMP7 | P09237 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP14 | P50281 | 1/20 | 0.50 |
| ▸ | MMP15 | P51511 | 1/20 | 0.50 |
| ▸ | MMP16 | P51512 | 1/20 | 0.50 |
| ▸ | ADAM33 | Q9BZ11 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5884548 | 0.89 | ADAM17 (0.60) | MMP13ADAMTS4ADAM17MMP2MMP1 | |
| SCHEMBL6263430 | 0.88 | MMP13 (0.57) | MMP13ADAMTS4ADAM17MMP2MMP1 | |
| SCHEMBL5883980 | 0.82 | ADAM17 (0.57) | MMP13ADAMTS4ADAM17MMP2MMP1 | |
| SCHEMBL5884157 | 0.79 | ADAM17 (0.56) | MMP13ADAM17MMP2MMP1MMP3 | |
| SCHEMBL5883829 | 0.79 | ADAM17 (0.63) | MMP13ADAMTS4ADAM17MMP2MMP3 | |
| SCHEMBL6212594 | 0.79 | ADAM17 (0.63) | ADAM17MMP2MMP3 | |
| SCHEMBL5884193 | 0.78 | ADAM17 (0.53) | MMP13ADAM17MMP2MMP1MMP3 | |
| SCHEMBL5884722 | 0.78 | ADAM17 (0.53) | MMP13ADAMTS4ADAM17MMP2 | |
| SCHEMBL5883940 | 0.78 | ADAM17 (0.66) | MMP13ADAMTS4ADAM17MMP2 | |
| SCHEMBL5884767 | 0.78 | LTA4H (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7102008-B2 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040063698-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004012663-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063698-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | MMP9, ADAM17, MMP3 | MMP13 8/4885ADAMTS4 30/4885ADAM17 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.